vs

Side-by-side financial comparison of PennyMac Mortgage Investment Trust (PMT) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.

PennyMac Mortgage Investment Trust is the larger business by last-quarter revenue ($93.6M vs $66.0M, roughly 1.4× SOLENO THERAPEUTICS INC). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs 39.4%, a 16.6% gap on every dollar of revenue.

PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.

SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.

PMT vs SLNO — Head-to-Head

Bigger by revenue
PMT
PMT
1.4× larger
PMT
$93.6M
$66.0M
SLNO
Higher net margin
PMT
PMT
16.6% more per $
PMT
56.0%
39.4%
SLNO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
PMT
PMT
SLNO
SLNO
Revenue
$93.6M
$66.0M
Net Profit
$52.4M
$26.0M
Gross Margin
98.3%
Operating Margin
38.6%
33.5%
Net Margin
56.0%
39.4%
Revenue YoY
-13.3%
Net Profit YoY
12.5%
134.0%
EPS (diluted)
$0.49
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PMT
PMT
SLNO
SLNO
Q4 25
$93.6M
Q3 25
$99.2M
$66.0M
Q2 25
$70.2M
$32.7M
Q1 25
$44.5M
Q4 24
$107.9M
Q3 24
$80.9M
Q2 24
$71.2M
Q1 24
$74.2M
Net Profit
PMT
PMT
SLNO
SLNO
Q4 25
$52.4M
Q3 25
$58.3M
$26.0M
Q2 25
$7.5M
$-4.7M
Q1 25
$9.7M
Q4 24
$46.5M
Q3 24
$41.4M
Q2 24
$25.4M
Q1 24
$47.6M
Gross Margin
PMT
PMT
SLNO
SLNO
Q4 25
Q3 25
98.3%
Q2 25
97.9%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
PMT
PMT
SLNO
SLNO
Q4 25
38.6%
Q3 25
47.4%
33.5%
Q2 25
24.2%
-20.0%
Q1 25
-14.2%
Q4 24
51.1%
Q3 24
32.8%
Q2 24
40.2%
Q1 24
43.6%
Net Margin
PMT
PMT
SLNO
SLNO
Q4 25
56.0%
Q3 25
58.7%
39.4%
Q2 25
10.7%
-14.4%
Q1 25
21.8%
Q4 24
43.1%
Q3 24
51.2%
Q2 24
35.7%
Q1 24
64.2%
EPS (diluted)
PMT
PMT
SLNO
SLNO
Q4 25
$0.49
Q3 25
$0.55
$0.47
Q2 25
$-0.04
$-0.09
Q1 25
$-0.01
Q4 24
$0.45
Q3 24
$0.36
Q2 24
$0.17
Q1 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PMT
PMT
SLNO
SLNO
Cash + ST InvestmentsLiquidity on hand
$190.5M
$498.9M
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$1.9B
$494.8M
Total Assets
$21.3B
$599.9M
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PMT
PMT
SLNO
SLNO
Q4 25
$190.5M
Q3 25
$181.0M
$498.9M
Q2 25
$108.6M
$286.8M
Q1 25
$204.2M
Q4 24
$103.2M
Q3 24
$102.8M
Q2 24
$336.3M
Q1 24
$343.3M
Total Debt
PMT
PMT
SLNO
SLNO
Q4 25
$1.1B
Q3 25
$299.0M
Q2 25
$1.2B
Q1 25
$968.4M
Q4 24
$1.0B
Q3 24
$5.2B
Q2 24
$5.4B
Q1 24
$5.1B
Stockholders' Equity
PMT
PMT
SLNO
SLNO
Q4 25
$1.9B
Q3 25
$1.9B
$494.8M
Q2 25
$1.9B
$240.1M
Q1 25
$1.9B
Q4 24
$1.9B
Q3 24
$1.9B
Q2 24
$1.9B
Q1 24
$2.0B
Total Assets
PMT
PMT
SLNO
SLNO
Q4 25
$21.3B
Q3 25
$18.5B
$599.9M
Q2 25
$16.8B
$332.3M
Q1 25
$14.9B
Q4 24
$14.4B
Q3 24
$13.1B
Q2 24
$12.1B
Q1 24
$12.3B
Debt / Equity
PMT
PMT
SLNO
SLNO
Q4 25
0.58×
Q3 25
0.16×
Q2 25
0.65×
Q1 25
0.51×
Q4 24
0.52×
Q3 24
2.70×
Q2 24
2.76×
Q1 24
2.60×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PMT
PMT
SLNO
SLNO
Operating Cash FlowLast quarter
$-7.2B
$43.5M
Free Cash FlowOCF − Capex
$43.5M
FCF MarginFCF / Revenue
65.8%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
-137.76×
1.67×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PMT
PMT
SLNO
SLNO
Q4 25
$-7.2B
Q3 25
$-1.3B
$43.5M
Q2 25
$-2.0B
$-12.6M
Q1 25
$-594.3M
Q4 24
$-2.7B
Q3 24
$-983.8M
Q2 24
$243.8M
Q1 24
$-342.4M
Free Cash Flow
PMT
PMT
SLNO
SLNO
Q4 25
Q3 25
$43.5M
Q2 25
$-12.6M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
PMT
PMT
SLNO
SLNO
Q4 25
Q3 25
65.8%
Q2 25
-38.6%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
PMT
PMT
SLNO
SLNO
Q4 25
Q3 25
0.0%
Q2 25
0.0%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
PMT
PMT
SLNO
SLNO
Q4 25
-137.76×
Q3 25
-22.26×
1.67×
Q2 25
-267.53×
Q1 25
-61.39×
Q4 24
-58.08×
Q3 24
-23.76×
Q2 24
9.59×
Q1 24
-7.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PMT
PMT

Other$55.0M59%
Interest Rate Sensitive Strategies$31.4M34%
Correspondent Production$7.2M8%

SLNO
SLNO

Segment breakdown not available.

Related Comparisons